Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Coupang Inc (CPNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Coupang Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Coupang Inc trades at $18.8 (market cap $33.75B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Coupang Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CPNG | |
|---|---|---|
Market Cap | $39.89B | $33.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $33.53 |
52-Week Low | $278.09 | $15.12 |
Enterprise Value | $38.15B | $32.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Coupang (CPNG) trades at $18.80, down 1.88% on the day, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $34.53B in 2025, though net income margins remain thin at 0.6%. The stock faces headwinds from a recent $409 million regulatory fine in South Korea over a data breach, as reported by Reuters on June 10, 2026, but maintains strong analyst support with 14 buy ratings.
The outlook is cautiously optimistic given Wall Street's $25.80 price target, implying 37% upside, but risks include regulatory scrutiny and volatile earnings. Positive cash flow from operations of $1.77B in 2025 supports growth initiatives, yet investors must weigh competitive pressures in e-commerce against the company's scale advantages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
